PF-Atlas › Clinical Trials › NCT07221227
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Efimosfermin alfa · Phase 3
Registry ID
NCT07221227
Phase
Phase 3
Status
Recruiting
Drug / intervention
Efimosfermin alfa
Sponsor
GlaxoSmithKline
Start
2025-10-24
Enrollment
1200
Locations
91
About this trial
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07221227 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.